The 20 Best Non-Small Cell Lung Cancer (NSCLC) Doctors Near Me

Gary Schwartz is a Hematologist Oncology provider practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 47 years. Dr. Schwartz is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Fibrosarcoma, Hepato-Pancreato-Biliary Surgery, and Liver Embolization. Dr. Schwartz is board certified in American Board Of Internal Medicine, 1986.

Suresh Ramalingam is an Oncologist practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 34 years. Dr. Ramalingam is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Ramalingam is board certified in American Board Of Internal Medicine, 2003.

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Triple-Negative Breast Cancer. Dr. Tolaney is board certified in Medical Oncology.

Roger Stupp is a Hematologist Oncology specialist and a Neurologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 39 years. Dr. Stupp is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri.

Charu Aggarwal is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Aggarwal is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Aggarwal is board certified in Medical Oncology, 2011. Dr. Aggarwal is currently accepting new patients.

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Brahmer is board certified in American Board Of Internal Medicine.

Dr. O'Shaughnessy is a Medical Oncologist that focuses on breast cancer prevention and treatment. She founded The School of Breast Oncology, a program providing a curriculum-based program focused exclusively on breast cancer clinical management. Dr. O'Shaughnessy attended medical school at Yale University School of Medicine in New Haven, CT. She then completed her Internal Medicine residency at Massachusetts General Hospital in Boston, MA and a Medical Oncology fellowship at National Cancer Institute in Bethesda, MD. She is co-chair of Breast Cancer Research, chair of Breast Cancer Prevention Research at Baylor Charles A. Sammons Cancer Center and a member of the Scientific Advisory Board for US Oncology Research Network. Dr. O'shaughnessy is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Inflammatory Breast Cancer, and Tissue Biopsy. Dr. O'shaughnessy is board certified in Medical Oncology- American Board Of Internal Med/Medical Oncology, Internal Medicine- American Board Of Internal Med, Internal Medicine- American Board Of Internal Medicine, and Medical Oncology- American Board Of Internal Medicine.

When someone is faced with a diagnosis of lung cancer, they may be going through surgery, radiation treatment, chemotherapy or enrolling in a clinical trial. It’s a very complicated process to understand what’s involved and what may happen next. It’s also hard to hear all the answers if you’re by yourself. We encourage our patients to come with family members and friends and loved ones and particularly to identify one or two main go-to people in terms of care-giving and support. That way we can engage them in the whole process. Just as we have a team taking care of the patient, the patient has a team, too. At Duke, we have the opportunity to engage patients in the very latest treatment approaches, whether it’s a new surgical technique, the latest radiation approach, or some novel chemotherapy, immunology, or targeted therapy, several of which we’ve been developing. Duke provides patients with a real opportunity that they may not have elsewhere. Dr. Crawford is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Febrile Neutropenia, Agranulocytosis, Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). Dr. Crawford is board certified in American Board Of Internal Med, Hematology/Oncology , American Board Of Internal Med, Internal Medicine , and American Board Of Internal Med, Medical Oncology.

I am a part of the thoracic oncology program. I work with patients who have cancers of the lung, which includes non-small cell lung cancer, small cell lung cancer, and mesothelioma. My focus is on clinical care, clinical trials, and developing new therapies for these diseases. When I first meet with a patient, I want them to understand what their diagnosis is, because there are actually multiple diagnoses of lung cancer and each are treated differently. Then I discuss with a patient whether they are a candidate for therapies such as molecular therapy or immunotherapy, and make sure they have a clear understanding of the treatment plan. There are some very promising new therapies for these diseases and we are fortunate to have those available to patients here at Duke. That’s one of the unique things we offer as an academic medical center. Dr. Stinchcombe is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery. Dr. Stinchcombe is board certified in American Board Of Internal Med, Medical Oncology.

Susan Domchek is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Domchek is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 22 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Ovarian Cancer, BRCA Positive Breast Cancer, Salpingo-Oophorectomy, and Hormone Replacement Therapy (HRT). Dr. Domchek is board certified in Medical Oncology, 2001. Dr. Domchek is currently accepting new patients.

Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Laheru is board certified in American Board Of Internal Medicine.

Nadine Tung is an Internal Medicine specialist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Tung is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Ovarian Cancer, BRCA Positive Breast Cancer, Salpingo-Oophorectomy, and Hormone Replacement Therapy (HRT). Dr. Tung is board certified in American Board Of Internal Medicine.

Kevin Kalinsky is an Oncologist practicing medicine in Atlanta, Georgia. Dr. Kalinsky is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER2 Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Inflammatory Breast Cancer.

Adam M. Brufsky, MD, PhD, FACP, is professor of medicine at the University of Pittsburgh School of Medicine and also serves as the associate division chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine's Department of Medicine. Dr. Brufsky is the medical director of the Magee-Women's Cancer Program, part of the UPMC Hillman Cancer Center, and UPMC Hillman Cancer Center; associate director for clinical investigations at UPMC Hillman Cancer Center; and codirector of the Comprehensive Breast Cancer Center.Dr. Brufsky is board-certified in internal medicine and medical oncology. He earned a medical and doctor of philosophy degrees from the University of Connecticut School of Medicine in Farmington, Conn.; completed a residency at Brigham and Women's Hospital, Harvard Medical School, and a fellowship at Dana-Farber Cancer Institute.Dr. Brufsky is a member of professional organizations, such as American Medical Association, Massachusetts Medical Society, American College of Physicians, American Society of Clinical Oncology, American Association for Cancer Research, Allegheny County Medical Society, Pennsylvania Medical Society, and Pennsylvania Oncologic Society. An active researcher, Dr. Brufsky has numerous abstracts and research articles in leading journals, and is principal investigator on a number of research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army - Breast Cancer Research Program. Dr. Brufsky is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Breast Cancer in Men, and Gastrostomy. Dr. Brufsky is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Brufsky is currently accepting new patients.

My clinical practice if focused on the care of patients with breast cancer, particularly those diagnosed at a younger age and those with recurrence in the central nervous system. I am committed to the care of patients with breast cancer brain metastases, and I am honored to serve as the Medical Director of the Brain and Spine Metastases Program in the Duke Cancer Center. In this role, our multidisciplinary team provides well-coordinated care for patients with breast cancer and other solid tumor types that have metastasized to the central nervous system. In addition, I enjoy helping young women diagnosed with breast cancer navigate their treatment decisions to ensure both excellent medical care and attention to individual challenges, such as future fertility, sequelae of treatment on longer-term health, and impact on current and future relationships. When not working, I enjoy running, reading, and traveling with my family. Dr. Anders is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Brain Tumor, Triple-Negative Breast Cancer, and Metastatic Brain Tumor.

As a cancer doctor, I strive to provide the kind of care that I would want for my own family. My aim is to use my expertise, knowledge, and understanding of the human condition to empower patients. While scientific knowledge and approaches are at the core of what I do, I find it important to aim to integrate the human context into what my team and I offer patients and their families. Having lived, trained, and worked in different countries, including Australia, the United Kingdom, the Netherlands, and the United States, I have developed unique insights into the practice of medicine and cancer care around the world. These experiences have given me a broader perspective and helped inform my approach to individualized patient care. I see my ability to help patients as a privilege, and I do get enormous pleasure from being able to help. When not working, I am an avid reader and enjoy running, cycling, and spending time with my family. Dr. Khasraw is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Balazs Halmos, MD received his medical degree summa cum laude from Semmelweis University in Budapest, Hungary. He completed an internal medicine residency program at St. Dr. Halmos is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

Liza C. Villaruz, MD, is board-certified in medical oncology and hematology at UPMC Hillman Cancer Center, and she specializes in lung cancer and thoracic malignancies. Dr. Villaruz is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC). Dr. Villaruz is board certified in American Board Of Internal Medicine. Dr. Villaruz is currently accepting new patients.

Conor Steuer is an Oncologist practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 17 years. Dr. Steuer is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Tissue Biopsy, and Gastrostomy. Dr. Steuer is board certified in American Board Of Internal Medicine, 2015.

I am a medical oncologist and researcher who specializes in treating patients with lung cancer and head and neck cancer. I’ve been at Duke for eight years. I first realized I wanted to become a doctor in graduate school, because it gave me the opportunity to practically apply scientific evidence to help others. What I love most about my job is working with our research and clinical staff to come up with new and hopeful therapies for patients. When a patient comes to see me, I look at their past and current medical history, review their lab tests, and then work with a team to figure out which treatment would work best for them. If a patient comes from far away, we try to make sure we can fit in visits with all the relevant specialists before they leave. Outside of work, I enjoy exercising with friends and spending time with my children at their various activities. Dr. Ready is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Ready is board certified in American Board Of Internal Med, Internal Medicine.